NCT04090684View on ClinicalTrials.gov

Ciprofloxacin/Celecoxib Combination in Patients With ALS

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

January 20, 2022

Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
DRUG

Fixed dose combination Ciprofloxacin/Celecoxib

Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

Trial Locations (1)

85013

Barrow Neurological Institute, Phoenix

Sponsors
All Listed Sponsors
lead

NeuroSense Therapeutics Ltd.

INDUSTRY

NCT04090684 - Ciprofloxacin/Celecoxib Combination in Patients With ALS | Biotech Hunter | Biotech Hunter